<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059263</url>
  </required_header>
  <id_info>
    <org_study_id>2019 - 00774</org_study_id>
    <nct_id>NCT04059263</nct_id>
  </id_info>
  <brief_title>HFIP Ex-vivo Study</brief_title>
  <official_title>Impact of Hexafluoroisopropanol (HFIP) on the Inflammatory Response in Blood of Septic Patients (HFIP Ex-vivo Study). A Feasibility, Proof of Principle Project.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis, a multi organ failure caused by infectious diseases, is a major health burden with an&#xD;
      average mortality rate of 26%. Cells of the innate immune system of hosts recognize specific&#xD;
      patterns of pathogenic bacteria and trigger an inflammatory response. In case of sepsis, this&#xD;
      inflammatory response takes a deregulated course, expressing an overwhelming amount of&#xD;
      pro-inflammatory cytokines leading to a loosening of endothelial tight junctions, evasion of&#xD;
      intravasal fluids and proteins into the interstitium, as well as direct tissue damage&#xD;
      throughout an overproduction of reactive oxygen species by neutrophils. These pathological&#xD;
      changes of the host's proper immune system lead to a multi organ failure, which characterize&#xD;
      a clinical pathomechanism of sepsis. Several studies confirmed an immunomodulatory effect of&#xD;
      sevoflurane's primary metabolite hexafluoroisopropanol (HFIP) attenuating pro-inflammatory&#xD;
      cytokine expression with a consecutive improvement of organ function and survival in rodent&#xD;
      models of sepsis. Until now, there are no data available confirming this effect in septic&#xD;
      patients as well. With this study, the direct impact of sevoflurane's primary metabolite HFIP&#xD;
      on cytokine expression in the blood of septic patients will be investigated for the first&#xD;
      time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory response in blood of septic patients after application of HFIP</measure>
    <time_frame>IL-6 will be measured after 6 hours incubation.</time_frame>
    <description>Interleukine-6 (IL-6) will be measured with Enzyme-linked Immunosorbent Sandwich Assay as a surrogate marker of inflammatory response. Amount of IL-6 is compared between treated samples and control samples.</description>
  </primary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Sepsis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the emergency department of tertiary care hospital with suspicion of&#xD;
        an infection and a qSOFA score ≥ 2 points.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to the emergency ward with suspicion of infection and a qSOFA Score&#xD;
             ≥ 2 points (Respiratory frequency &gt; 22/minute, Systolic blood pressure &lt; 100 mmHg,&#xD;
             Glasgow Coma Scale &lt; 15).&#xD;
&#xD;
          -  Male and Female subjects with at least 18 years of age.&#xD;
&#xD;
          -  Written informed consent by the participant after information about the project. In&#xD;
             emergency cases where a written consent cannot be obtained immediately, due to the&#xD;
             patient's medical conditions, the existence of a patient decree and of a&#xD;
             representative in the emergency situation is evaluated according to the Swiss Civil&#xD;
             Code. Informed consent will be obtained from the representative. A medical doctor,&#xD;
             furthermore, not participating in the investigation, guarantees the medical care of&#xD;
             the patient by the defending of his/her interests. After recovery, the patient will be&#xD;
             informed as soon as possible about the trial and consent is requested.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acquired Immune Deficiency Syndrome&#xD;
&#xD;
          -  Anti-IL-6 therapy (e.g. Kevzara®) within the last 60 days&#xD;
&#xD;
          -  Application of a cytokine absorber&#xD;
&#xD;
          -  Pregnancy and/or Breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Beck Schimmer, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatrice Beck Schimmer, Prof. Dr. med</last_name>
    <phone>0446355035</phone>
    <email>beatrice.beckschimmer@uzh.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattia M. Müller</last_name>
      <phone>0446355035</phone>
      <email>mattia.mueller@uzh.ch</email>
    </contact>
    <investigator>
      <last_name>Beatrice Beck Schimmer, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Schläpfer Martin, PD Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Müller M. Mattia, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kern Sabine, study nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

